Literature DB >> 16948881

Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer.

Mehmet Kiliç1, Erdal Göçmen, Mesut Tez, Tamer Ertan, Mehmet Keskek, Mahmut Koç.   

Abstract

BACKGROUND: Pancreatic cancer carries a poor prognosis; at operation approximately 25% of patients will be found to have unresectable tumours even though CT has demonstrated that they are resectable. At our tertiary care centre, we wished to find out if there is an optimum cut-off value for the CA 19-9 level preoperatively that will indicate that the pancreatic cancer is unresectable despite radiologic imaging that suggests otherwise according to receiver operating characteristic (ROC) curve analysis.
METHODS: Preoperative demographic data, clinical features and serum CA 19-9 levels were reviewed for 51 patients with pancreatic cancer who underwent laparotomy between 1998 and 2003. Preoperatively, resectability was determined from a complete history, physical examination and radiologic imaging. An ROC curve was constructed for the CA 19-9 levels. The sensitivity, specificity, positive and negative predictive values of CA 19-9 were calculated with several cut-off points.
RESULTS: There were 18 (36%) resectable and 33 (64%) unresectable pancreatic cancers. The mean CA 19-9 level was 68.8 U/mL in the resectable group and 622 U/mL in unresectable group. When a CA 19-9 level of 256.4 U/mL was used as a cutoff point, the specificity and sensitivity was 92.3% and 82.4% respectively.
CONCLUSION: Preoperative CA 19-9 levels may be a useful marker for determining preoperatively which patients have unresectable disease despite the demonstration on CT of resectable disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16948881      PMCID: PMC3207573     

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  13 in total

Review 1.  Surgical and medical therapy for pancreatic carcinoma.

Authors:  Conor J Magee; Paula Ghaneh; John P Neoptolemos
Journal:  Best Pract Res Clin Gastroenterol       Date:  2002-06       Impact factor: 3.043

Review 2.  Laparoscopy in the staging of pancreatic cancer.

Authors:  P W Pisters; J E Lee; J N Vauthey; C Charnsangavej; D B Evans
Journal:  Br J Surg       Date:  2001-03       Impact factor: 6.939

3.  Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database.

Authors:  S F Sener; A Fremgen; H R Menck; D P Winchester
Journal:  J Am Coll Surg       Date:  1999-07       Impact factor: 6.113

4.  Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.

Authors:  D V Mann; R Edwards; S Ho; W Y Lau; G Glazer
Journal:  Eur J Surg Oncol       Date:  2000-08       Impact factor: 4.424

5.  Receiver operating characteristic curves to assess predictors of radiation-induced symptomatic lung injury.

Authors:  Pehr A Lind; Lawrence B Marks; Donna Hollis; Ming Fan; Su-Min Zhou; Michael T Munley; Timothy D Shafman; Ronald J Jaszczak; R Edward Coleman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-10-01       Impact factor: 7.038

6.  Utility of tumor markers in determining resectability of pancreatic cancer.

Authors:  Michael G Schlieman; Hung S Ho; Richard J Bold
Journal:  Arch Surg       Date:  2003-09

7.  Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9.

Authors:  C E Forsmark; L Lambiase; S B Vogel
Journal:  Pancreas       Date:  1994-11       Impact factor: 3.327

8.  Preoperative diagnostics in pancreatic carcinoma: would less be better?

Authors:  T Böttger; R Engelman; J K Seifert; R Löw; T Junginger
Journal:  Langenbecks Arch Surg       Date:  1998-08       Impact factor: 3.445

9.  The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer.

Authors:  J Lundin; P J Roberts; P Kuusela; C Haglund
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

10.  CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.

Authors:  C Haglund; J Lundin; P Kuusela; P J Roberts
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

View more
  20 in total

Review 1.  Indications for staging laparoscopy in pancreatic cancer.

Authors:  Antonella De Rosa; Iain C Cameron; Dhanwant Gomez
Journal:  HPB (Oxford)       Date:  2015-11-18       Impact factor: 3.647

2.  Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma.

Authors:  Shun Zhang; Yi-Ming Wang; Chuan-Dong Sun; Yun Lu; Li-Qun Wu
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

3.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  J Gastrointest Oncol       Date:  2012-06

4.  CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer.

Authors:  Victor Molina; Laura Visa; Carles Conill; Salvador Navarro; Jose M Escudero; Jose M Auge; Xavier Filella; Miguel A Lopez-Boado; Joana Ferrer; Laureano Fernandez-Cruz; Rafael Molina
Journal:  Tumour Biol       Date:  2011-12-29

5.  CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort.

Authors:  Marta Herreros-Villanueva; Lourdes Ruiz-Rebollo; Mario Montes; Mario Rodriguez-Lopez; María Francisco; Joaquín Cubiella; Eduardo Iyo; Emilio Garabitos; Emma Martínez Moneo; Maider Martos; Enrique de Madaria; Ibon Martínez-Arránz; Marta García-Cougil; Agueda Iglesias-Gómez; Luis Bujanda
Journal:  Mol Biol Rep       Date:  2020-01-08       Impact factor: 2.316

6.  The Role of CA19-9 in Predicting Tumour Resectability in Carcinoma Head of Pancreas.

Authors:  Jayabal Pandiaraja; Subramanian Viswanathan; Thomas Babu Antomy; Sathyamoorthy Thirumuruganand; Dhandapani Subramanian Kumaresan
Journal:  J Clin Diagn Res       Date:  2016-03-01

Review 7.  The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.

Authors:  Katherine E Poruk; D Z Gay; K Brown; J D Mulvihill; K M Boucher; C L Scaife; M A Firpo; S J Mulvihill
Journal:  Curr Mol Med       Date:  2013-03       Impact factor: 2.222

8.  Diagnostic and prognostic biomarkers in pancreatic carcinoma.

Authors:  John J Liang; Eric T Kimchi; Kevin F Staveley-O'Carroll; Dongfeng Tan
Journal:  Int J Clin Exp Pathol       Date:  2008-04-12

9.  Utility of Viscoelastic Assays Beyond Coagulation: Can Preoperative Thrombelastography Indices Predict Tumor Histology, Nodal Disease, and Resectability in Patients Undergoing Pancreatectomy?

Authors:  Hunter B Moore; Alessandro Paniccia; Peter J Lawson; Robert J Torphy; Trevor L Nydam; Ernest E Moore; Martin D McCarter; Richard D Schulick; Barish H Edil
Journal:  J Am Coll Surg       Date:  2018-03-30       Impact factor: 6.113

10.  CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery.

Authors:  Chih-Po Hsu; Li-Yu Lee; Jun-Te Hsu; Yu-Pao Hsu; Yu-Tung Wu; Shang-Yu Wang; Chun-Nan Yeh; Tse-Ching Chen; Tsann-Long Hwang
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.